文献速递贫血与红细胞疾病

罗米司亭联合环孢素A治疗未接受过免疫抑制治疗的再生障碍性贫血患者:一项2/3期研究

Romiplostim with ciclosporin A in patients with aplastic anaemia naïve to immunosuppressive therapy: A phase 2/3 study.
PubMed 文献 · Br J Haematol · 2025-07-10

这项开放标签2/3期研究在日本和韩国纳入24例未接受过免疫抑制治疗的成人再生障碍性贫血患者,评估罗米司亭联合环孢素A的疗效与安全性。第27周总缓解率为41.7%(95%CI 22.1%-63.4%),亚组中极重型为0.0%、重型为46.2%、非重型为57.1%。近92%患者发生至少1例治疗中出现的不良事件,但无药物相关≥3级不良事件报告。

要点

  • 第27周总缓解率为41.7%(95%CI 22.1%-63.4%),极重型、重型、非重型亚组分别为0.0%、46.2%、57.1%。
  • 近92%患者发生至少1例治疗中出现的不良事件,但无药物相关≥3级不良事件报告。
  • 1例患者发生骨髓增生异常综合征。

核心结论

  • 罗米司亭联合环孢素A对未接受过免疫抑制治疗的再生障碍性贫血患者有效且耐受性良好。

研究设计与样本

  • 开放标签2/3期研究(NCT04095936),在日本和韩国招募未接受过免疫抑制治疗的成人再生障碍性贫血患者,评估罗米司亭联合环孢素A的疗效与安全性。
  • 共纳入24例患者(中位年龄52岁,范围19-80岁),22例(91.7%)完成研究;其中极重型再生障碍性贫血4例(16.7%),重型13例(54.2%),输血依赖型非重型7例(29.2%)。
  • 罗米司亭自10 μg/kg每周1次起始至第4周,第5周起在0至20 μg/kg之间调整;环孢素A以5-6 mg/kg/日分两次给药至第26周。

主要发现

  • 第27周观察到10/24例患者出现血液学缓解,总缓解率为41.7%(95%CI 22.1%-63.4%)。
  • 第27周亚组总缓解率:极重型再生障碍性贫血为0.0%,重型为46.2%,非重型为57.1%。
  • 近92%患者经历至少1例治疗中出现的不良事件,但未报告药物相关≥3级治疗中出现的不良事件。
  • 1例患者发生骨髓增生异常综合征。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Romiplostim has been shown to restore multi-lineage haematopoiesis and is effective in patients with aplastic anaemia (AA) refractory to immunosuppressive therapy (IST). This open-label, phase 2/3 study (NCT04095936) recruited adult AA patients in Japan and Korea who had not received prior IST and evaluated the efficacy and safety of romiplostim plus ciclosporin A (CsA). Romiplostim was initiated at 10 μg/kg once weekly through Week 4 and adjusted between 0 and 20 μg/kg from Week 5 onwards. CsA was administered at 5-6 mg/kg/day in two divided doses through Week 26. A total of 24 patients (median [range] age, 52 [19-80] years) were enrolled, and 22 (91.7%) completed the study. Four patients (16.7%) had very severe AA (VSAA), 13 (54.2%) had severe AA (SAA) and seven (29.2%) had transfusion-dependent non-severe AA (NSAA). A haematological response at Week 27 was observed in 10/24 patients (overall response, 41.7%; 95% confidence interval, 22.1%-63.4%). At Week 27, the subgroup overall response rates were 0.0% in VSAA, 46.2% in SAA and 57.1% in NSAA. Nearly 92% of patients experienced at least one treatment-emergent adverse event (TEAE), but no drug-related Grade ≥3 TEAEs were reported. One patient developed myelodysplastic syndromes. Treatment with romiplostim plus CsA was effective and well tolerated in patients with AA who had not previously received IST.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Lee JW, Jang JH, Chiba S, et al. Romiplostim with ciclosporin A in patients with aplastic anaemia naïve to immunosuppressive therapy: A phase 2/3 study. Br J Haematol. 2025. PMID: 40639944. doi:10.1111/bjh.20206

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。